OmniAb, Inc. (OABI): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$36.45M

Year ended 2025-12-31

-$17.67M

Trailing 12 months to 2026-06-30

2021-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$36.45M	n/m	2026-03-04, From 2025-01-01
2024-12-31	-$39.66M	n/m	2026-03-04, From 2024-01-01
2023-12-31	$2.35M	n/m	2025-03-18, From 2023-01-01
2022-12-31	-$3.59M	n/m	2024-03-25, From 2022-01-01
2021-12-31	-$5.67M	n/a	2023-03-30, From 2021-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
OmniAb, Inc. (OABI)	2025-12-31	-$36.45M	n/m
Foxo Technologies Inc. (FOXO)	2025-12-31	-$3.87M	n/m
MaxCyte, Inc. (MXCT)	2025-12-31	-$34.41M	n/m
bioAffinity Technologies, Inc. (BIAF)	2025-12-31	-$9.33M	n/m
Absci Corp (ABSI)	2025-12-31	-$92.92M	n/m
NRC Health (NRC)	2025-12-31	$26.45M	-23.6%
iSpecimen Inc. (ISPC)	2025-12-31	-$4.24M	n/m
OneMedNet Corp (ONMD)	2025-12-31	-$7.50M	n/m
Cannabis Bioscience International Holdings, Inc. (CBIH)	2025-05-31	-$329.6K	n/m

Compare OABI, FOXO, MXCT, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗